{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:00Z","timestamp":1792600980578,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eclinm.2026.103991","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T20:35:43Z","timestamp":1779741343000},"page":"103991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making"],"prefix":"10.1016","volume":"96","author":[{"given":"Areesha","family":"Moiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana H.Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-0088","authenticated-orcid":false,"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1296-0661","authenticated-orcid":false,"given":"Mark J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103991_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2026.103991_bib3","series-title":"Medication Treatments for Diabetes and Obesity in Canada, 2019\u20132023","year":"2024"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103991_bib4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib6","doi-asserted-by":"crossref","first-page":"bqae155","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"issue":"10S","key":"10.1016\/j.eclinm.2026.103991_bib7","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001038476.01350.d1","article-title":"S2277 the role of glucagon-like peptide-1 agonists on gastric emptying measured by scintigraphy imaging","volume":"119","author":"KogilathotaJagirdhar","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like Peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103991_bib9","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1111\/dom.70040","article-title":"Mazdutide reduces body weight in adults with overweight or obesity: a high-dose phase 1 trial","volume":"27","author":"Bhattachar","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103991_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib11","article-title":"Efficacy and safety of GLP-1 agonists in the treatment of T2DM: a systematic review and network meta-analysis","volume":"15","author":"Ren","year":"2025","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103991_bib12","first-page":"846","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2026.103991_bib14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103991_bib15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103991_bib16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103991_bib17","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae122","article-title":"Semaglutide concurrently improves vascular and liver indices in patients with type 2 diabetes and fatty liver disease","volume":"8","author":"Korakas","year":"2024","journal-title":"J Endocr Soc"},{"issue":"21","key":"10.1016\/j.eclinm.2026.103991_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/nu14214673","article-title":"Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.eclinm.2026.103991_bib19","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103991_bib20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.eclinm.2026.103991_bib21","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103991_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.eclinm.2026.103991_bib23","article-title":"Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: a single-center study","volume":"2","author":"Srinivasan","year":"2022","journal-title":"Obes Pillars"},{"issue":"18","key":"10.1016\/j.eclinm.2026.103991_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12185915","article-title":"Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies","volume":"12","author":"Szczesnowicz","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"10103","key":"10.1016\/j.eclinm.2026.103991_bib26","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.eclinm.2026.103991_bib27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103991_bib28","article-title":"A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson's disease","author":"Hogg","year":"2022","journal-title":"SSRN J"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int J Eat Disord"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"Lahteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.eclinm.2026.103991_bib34","first-page":"143","article-title":"Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review","volume":"14","author":"Haran","year":"2024","journal-title":"Psoriasis (Auckl)"},{"issue":"21","key":"10.1016\/j.eclinm.2026.103991_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review","volume":"25","author":"Halloum","year":"2024","journal-title":"J Headache Pain"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103991_bib37","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.eclinm.2026.103991_bib38","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.103991_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103991_bib42","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00361.2023","article-title":"Maternal GLP-1 receptor activation inhibits fetal growth","volume":"326","author":"Qiao","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"43","key":"10.1016\/j.eclinm.2026.103991_bib43","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.240768","article-title":"Glucagon-like peptide-1 receptor agonists during pregnancy and lactation","volume":"196","author":"Zipursky","year":"2024","journal-title":"Can Med Assoc J"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103991_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.eclinm.2026.103991_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251383064","article-title":"The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials","volume":"16","author":"Hoteit","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/GCO.0000000000001015","article-title":"GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence","volume":"37","author":"Mikdachi","year":"2025","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MOP.0000000000001365","article-title":"Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice","volume":"36","author":"Bensignor","year":"2024","journal-title":"Curr Opin Pediatr"},{"issue":"14","key":"10.1016\/j.eclinm.2026.103991_bib49","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.1503\/cmaj.241456","article-title":"Managing obesity in children: a clinical practice guideline","volume":"197","author":"Ball","year":"2025","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.eclinm.2026.103991_bib50","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA adverse event reporting system database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol"},{"issue":"22","key":"10.1016\/j.eclinm.2026.103991_bib51","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1001\/jama.2023.16620","article-title":"As semaglutide's popularity soars, rare but serious adverse effects are emerging","volume":"330","author":"Ruder","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.103991_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080679","article-title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study","volume":"388","author":"Shapiro","year":"2025","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103991_bib54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103991_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.eclinm.2026.103991_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70512","article-title":"The pancreatic signal of GLP-1 receptor agonists: a biliary phenomenon rather than direct toxicity","author":"Koren","year":"2026","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib57","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.eclinm.2026.103991_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103991_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1520313","article-title":"Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?","volume":"15","author":"Resnick","year":"2025","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial","volume":"31","author":"Pasqua","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103991_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.obmed.2025.100591","article-title":"GLP-1 agonists in type 1 diabetes \u2013 indications and use","volume":"54","author":"Panjawatanan","year":"2025","journal-title":"Obesity Medicine"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103991_bib63","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the adjunct one treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103991_bib64","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the adjunct two randomized trial","volume":"39","author":"Ahren","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103991_bib65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103991_bib66","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3803\/EnM.2025.2696","article-title":"Rapid glycemic correction and the paradox of retinopathy progression","volume":"40","author":"Choe","year":"2025","journal-title":"Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103991_bib67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4239\/wjd.v15.i3.311","article-title":"Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: the pathobiology and therapeutic implications","volume":"15","author":"Blaibel","year":"2024","journal-title":"World J Diabetes"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib68","first-page":"52","article-title":"Reducing or discontinuing insulin or sulfonylurea when initiating a glucagon-like peptide-1 agonist","volume":"41","author":"Herron","year":"2024","journal-title":"Fed Pract"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib69","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00464-024-11263-2","article-title":"Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"39","author":"Kindel","year":"2025","journal-title":"Surg Endosc"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib70","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"El-Boghdadly","year":"2025","journal-title":"Anaesthesia"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib71","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103991_bib72","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib74","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib75","article-title":"Euglycemic ketoacidosis in a non-diabetic patient after tirzepatide use: a cautionary tale","volume":"17","author":"Singh","year":"2025","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib76","article-title":"A case of euglycemic diabetic ketoacidosis with tirzepatide use and severe calorie restriction","volume":"4","author":"Raptis","year":"2026","journal-title":"JCEM Case Rep"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib77","article-title":"Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes","volume":"4","author":"Kemmotsu","year":"2026","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.eclinm.2026.103991_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jemermed.2026.01.002","article-title":"Tirzepatide-associated euglycemic diabetic ketoacidosis in the absence of sodium-glucose cotransporter-2 inhibitor use: a case report","volume":"83","author":"Campana","year":"2026","journal-title":"J Emerg Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Martinez","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib80","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the obesity society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194740","article-title":"The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib82","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000516418","article-title":"Excess body weight and gallstone disease","volume":"37","author":"Stokes","year":"2021","journal-title":"Visc Med"},{"key":"10.1016\/j.eclinm.2026.103991_bib83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajh\/hpaf205","article-title":"GLP-1 receptor agonists and blood pressure: a state-of-the-art review of mechanisms, evidence, and clinical implications","volume":"39","author":"Moiz","year":"2026","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103991_bib84","doi-asserted-by":"crossref","first-page":"e2080","DOI":"10.1210\/clinem\/dgae722","article-title":"Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists","volume":"110","author":"Kelly","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2026.103991_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.eclinm.2026.103991_bib86","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1111\/dom.70666","article-title":"Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials","volume":"28","author":"Eisa","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2026.103991_bib87","doi-asserted-by":"crossref","DOI":"10.7326\/ANNALS-25-00478","article-title":"Effect of incretin-based and nonpharmacologic weight loss on body composition : a systematic review","author":"Batsis","year":"2026","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103991_bib88","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103991_bib89","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103991_bib90","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jama.2025.11153","article-title":"Managing adverse effects of incretin-based medications for obesity","volume":"334","author":"Kushner","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103991_bib91","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/oby.24336","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"33","author":"Mozaffarian","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.eclinm.2026.103991_bib92","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamainternmed.2025.8222","article-title":"Heterogeneity of treatment effects of glucagon-like Peptide-1 receptor agonists for weight loss in adults: a systematic review and meta-analysis","volume":"186","author":"Alexander","year":"2026","journal-title":"JAMA Intern Med"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2026.103991_bib93","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.2337\/dc26-S008","article-title":"Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103991_bib94","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2026.103991_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/oby.70179","article-title":"Real-world weight-loss outcomes in weight-reduced patients treated with tirzepatide","author":"Barenbaum","year":"2026","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103991_bib96","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.eclinm.2026.103991_bib97","series-title":"Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists: Report","author":"Vannabouathong","year":"2022"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103991_bib98","doi-asserted-by":"crossref","DOI":"10.1111\/hex.70251","article-title":"What are the experiences, views and perceptions of patients, carers and clinicians of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)? A scoping review","volume":"28","author":"Febrey","year":"2025","journal-title":"Health Expect"},{"key":"10.1016\/j.eclinm.2026.103991_bib99","first-page":"284","article-title":"Engaging patients in decision-making and behavior change to promote prevention","volume":"240","author":"Krist","year":"2017","journal-title":"Stud Health Technol Inform"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103991_bib100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nurpra.2016.05.013","article-title":"Obesity stigma and bias","volume":"12","author":"Fruh","year":"2016","journal-title":"J Nurse Pract"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103991_bib101","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199503093321001","article-title":"Changes in energy expenditure resulting from altered body weight","volume":"332","author":"Leibel","year":"1995","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.eclinm.2026.103991_bib102","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/ijo.2010.184","article-title":"Adaptive thermogenesis in humans","volume":"34","author":"Rosenbaum","year":"2010","journal-title":"Int J Obes"},{"key":"10.1016\/j.eclinm.2026.103991_bib103","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnut.2014.00007","article-title":"Neural responses to visual food cues according to weight status: a systematic review of functional magnetic resonance imaging studies","volume":"1","author":"Pursey","year":"2014","journal-title":"Front Nutr"},{"key":"10.1016\/j.eclinm.2026.103991_bib104","series-title":"Clinical Management of Obesity","author":"Apovian","year":"2025"},{"issue":"27","key":"10.1016\/j.eclinm.2026.103991_bib105","doi-asserted-by":"crossref","first-page":"E797","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"Can Med Assoc J"},{"issue":"31","key":"10.1016\/j.eclinm.2026.103991_bib106","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Can Med Assoc J"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:27:14Z","timestamp":1791232034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026002397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":103,"alternative-id":["S2589537026002397"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103991","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103992","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103991"}}